Biofrontera stock holds Buy rating at Benchmark despite Q3 net loss

Investing.com - Benchmark maintained its Buy rating and $3.00 price target on Biofrontera (NASDAQ:BFRI) following the company’s third-quarter earnings report. The stock currently trades at $0.84, having fallen 17.6% over the past week despite a 27.3% gain over the last six months.

Biofrontera reported third-quarter revenue that met expectations but posted a larger-than-anticipated net loss, according to Benchmark’s analysis released Friday. InvestingPro data shows the company is not profitable over the last twelve months and is quickly burning through cash, with a negative EBITDA of $16.08 million.

The research firm noted that Biofrontera management expects a strong fourth quarter as customers stock up ahead of an anticipated price increase for its Ameluz product, potentially leading to a net profit for the period.

Looking toward 2026, Biofrontera aims to achieve cost savings and operational efficiencies from the restructuring of agreements with its former parent company, Biofrontera AG.

The company anticipates important clinical milestones in early 2026, including data from its Phase 3 extremities trial and Phase 2b acne trial, with a potential supplemental New Drug Application submission for the extremities indication targeted for mid-2026.

In other recent news, Biofrontera Inc. reported its financial results for the third quarter of 2025, indicating a significant decline in revenue and an increase in net losses compared to the previous year. The company is addressing these financial challenges by focusing on strategic initiatives, such as new product developments and operational agreements. These developments are part of Biofrontera’s broader efforts to stabilize its financial standing and adapt to changing market conditions. There was a slight dip in premarket trading, reflecting investor sentiment toward the earnings report and the company’s future projections. While the company’s stock performance was impacted, no specific analyst upgrades or downgrades were noted in the available reports. Investors are closely watching Biofrontera’s strategic moves as it navigates this challenging financial period. The company’s focus on new products and agreements may play a crucial role in its future trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.